This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Monday's Health Winners & Losers

InSite Vision (ISV), an ophthalmic therapeutics, diagnostics and drug-delivery company, rose on news the Food and Drug Administration has accepted for filing and review the company's application for AzaSite. AzaSite is indicated for the treatment of bacterial conjunctivitis. Shares of InSite were gaining 5% to $1.69.

BioMarin Pharmaceutical (BMRN - Get Report) was higher following word that Orapred ODT, an orally disintegrating tablet form of prednisolone, is now commercially available in the U.S. BioMarin's shares were up 1% to $15.85.

St. Jude Medical (STJ - Get Report) ticked higher after the company said it would combine its cardiac surgery and cardiology divisions to create a new cardiovascular unit effective Jan. 1. Additionally, the company is initiating several changes to enhance the efficiency and effectiveness of its sales and customer service operations at certain international locations. Because of the restructuring, St. Jude expects to incur a pretax charge of $25 million to $35 million in the third quarter. St. Jude added 0.2% to $36.19.

Sinovac Biotech (SVA - Get Report), a Chinese biopharmaceutical company, jumped 17.3% to $2.37 after it said the preliminary results of a Phase I clinical trial showed that its vaccine against the H5N1 strain of avian flu had a high safety and immunogenicity profile.

Epix Pharmaceuticals (EPIXD) dropped after it received a letter from the Food and Drug Administration denying its formal appeal to approve its novel blood-pool imaging agent Vasovist and turning down the company's request for an advisory committee review. Shares of Epix were lower by 12.9% to $6.28.

Shares of Corcept Therapeutics (CORT - Get Report) were weaker for a second day, falling 10.4% to $1.38. The stock plunged Friday after the company announced negative results from a clinical trial on its experimental psychotic depression drug Corlux.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BMRN $64.62 -5.50%
CORT $3.45 1.80%
STJ $50.31 -1.80%
SVA $6.71 -4.80%
AAPL $95.24 1.30%


Chart of I:DJI
DOW 16,027.05 -177.92 -1.10%
S&P 500 1,853.44 -26.61 -1.42%
NASDAQ 4,283.7530 -79.3910 -1.82%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs